Gogola Alexandra, Zeng Xuemei, Williams Lilcelia A, Chapple-McGruder Theresa, Saeed Anum, Lopresti Brian J, Snitz Beth, Tudorascu Dana, Minhas Davneet, Ikonomovic Milos D, Kofler Julia, Matan Cristy, Pascoal Tharick A, Aizenstein Howard, Zetterberg Henrik, Blennow Kaj, Lopez Oscar, Villemagne Victor L, Karikari Thomas K, Cohen Ann D
Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Alzheimers Dement. 2025 Jul;21(7):e70463. doi: 10.1002/alz.70463.
Given the predominance of imaging and plasma biomarkers in Alzheimer's disease observational studies and clinical trials, it is critical to understand the differences between these biomarkers across racialized groups.
A total of 260 older adults without dementia racialized as Black and/or African American (AA) and non-Hispanic white (NHW), ranging in age from 50 to 90 years (68.8 ± 9.1 years), were evaluated for differences in plasma amyloid-β (Aβ) 42/Aβ40, p-tau181, p-tau217, p-tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) as well as Aβ positron emission tomography (PET) and magnetic resonance (MR) imaging-derived cortical thickness using Mann-Whitney U tests and analysis of covariance (ANCOVA).
Both Mann-Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global [C]-Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p-tau181, and p-tau231 values (p < 0.05).
Racialization should be given more consideration in AD clinical research, particularly when biomarker results are used for inclusion or exclusion criteria for clinical trials and qualification in clinical practice.
Global [C]-Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness, p-tau181, and p-tau231 differed between groups Differences were unaffected by age, sex, apolipoprotein E 4 (APOE4), education, and Mini-Mental State Examination (MMSE) score Racialization needs more consideration in Alzheimer's disease clinical research Additional work is needed to understand the sources of biomarker differences.
鉴于影像学和血浆生物标志物在阿尔茨海默病观察性研究和临床试验中的主导地位，了解这些生物标志物在不同种族群体之间的差异至关重要。
对260名年龄在50至90岁（平均68.8±9.1岁）、未患痴呆症的老年人进行了评估，这些老年人按种族分为黑人/非裔美国人（AA）和非西班牙裔白人（NHW），比较他们血浆中淀粉样蛋白-β（Aβ）42/Aβ40、磷酸化tau蛋白181（p-tau181）、磷酸化tau蛋白217（p-tau217）、磷酸化tau蛋白231（p-tau231）、神经丝轻链（NfL）和胶质纤维酸性蛋白（GFAP）的差异，以及Aβ正电子发射断层扫描（PET）和磁共振（MR）成像得出的皮质厚度差异，采用曼-惠特尼U检验和协方差分析（ANCOVA）。
曼-惠特尼检验和ANCOVA均发现，在全局[C]-匹兹堡化合物B（PiB）标准化摄取值比率（SUVR）、皮质厚度值、p-tau181和p-tau231值方面，AA组和NHW组之间存在显著差异（p<0.05）。
在AD临床研究中应更多地考虑种族因素，尤其是当生物标志物结果被用作临床试验的纳入或排除标准以及临床实践中的资格标准时。
全局[C]-匹兹堡化合物B（PiB）标准化摄取值比率（SUVR）、皮质厚度、p-tau181和p-tau231在不同组之间存在差异 差异不受年龄、性别、载脂蛋白E 4（APOE4）、教育程度和简易精神状态检查表（MMSE）评分的影响 在阿尔茨海默病临床研究中需要更多地考虑种族因素 需要开展更多工作来了解生物标志物差异的来源。
